International Journal of Radiation Oncology*Biology*Physics
Clinical investigationNecessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer
Introduction
Neck dissection has traditionally played an important role in the treatment of patients with squamous cell carcinoma of the head and neck who present with regionally advanced neck disease (N2-N3). This strategy evolved in the early 1970s from the recognition that the rate of ipsilateral neck recurrence was lower in those patients who received combined radiotherapy (RT) and surgery compared with either of those modalities alone (1). Modified fractionation regimens were initially adopted in the 1980s and facilitated the delivery of more efficacious, higher doses of RT. Despite this more intensive approach, the regional control rates remained greater with the incorporation of neck dissection into the treatment plan (2).
The emergence of RT and concurrent chemotherapy regimens in the 1990s led to additional improvements in treatment efficacy. A meta-analysis of >8000 patients treated on randomized trials through 1993 demonstrated an 8% absolute survival benefit for concurrent therapy over RT alone for patients with advanced disease (3). Many of the trials included in that analysis used regimens of RT and/or chemotherapy now known to be substandard. Several randomized trials with a cumulative enrollment of >1500 patients, all of which used state of the art RT and chemotherapy regimens, have been published since 1993. Each of these trials has demonstrated absolute improvement of approximately 20% in both locoregional control and overall survival 4, 5, 6, 7, 8, 9, 10, 11.
The necessity for neck dissection after concurrent chemoradiation is controversial 12, 13. Some have suggested that it is either superfluous or ineffective in this setting and should be abandoned (14). The rationale for this line of argument is that a clinical/radiographic complete response (CR) in the neck indicates total disease eradication and that additional surgery will not reduce the risk of regional recurrence; rather, it will only increase morbidity. The other contention of this viewpoint is that neck dissections are ineffective for patients with advanced disease because improvements in regional control do not reduce the propensity for distant failure and thus do not improve survival. Others assert that clinical parameters do not identify those who do not need the procedure.
This report constitutes the first analysis of the efficacy of neck dissection for patients with advanced neck disease receiving concurrent chemoradiation at Duke University Medical Center. Published data specifically addressing the role of neck dissection after concurrent chemoradiation are sparse 12, 13, 15, 16. An evaluation of the previously published data on this topic is also presented. Our overall intent was to define the value of neck dissection in this patient population better.
Section snippets
Methods and materials
Patients with locally advanced squamous carcinoma of the head and neck who also presented with nodal disease and underwent hyperfractionated RT and concurrent cisplatin/5-fluorouracil chemotherapy constituted the study population. This treatment program has been used at Duke University Medical Center since 1990. The details of this regimen have been previously published (9).
Adjuvant modified neck dissection (MND) was planned 6 to 8 weeks after completion of chemoradiation in those patients who
Results
Between 1990 and 2000, 154 patients received concurrent chemoradiation. Of these, 108 presented with nodal disease: 30 with N1, 62 with N2 (N2a, 23; N2b, 20; and N2c, 19), and 16 with N3. MND was performed in 65 (60%) of 108 patients, including 13 (43%) of 30 with N1, 43 (69%) of 62 with N2, and 9 (56%) of 16 with N3. Eighty-three percent of these patients presented with a T3-T4 primary. The primary tumor location was the oropharynx in 64%, larynx in 16%, hypopharynx in 13%, and oral cavity in
Discussion
The results of this study showed a therapeutic benefit associated with the incorporation of adjuvant MND into the treatment program for patients with N2-N3 neck disease and undergoing a course of concurrent chemoradiation. Patients who had a cCR in the neck and who did not have subsequent neck dissection had worse disease-free and overall survival than those patients who underwent neck dissection, irrespective of the clinical neck response in the latter group. This observation suggests that
References (31)
- et al.
Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx
Am J Surg
(1972) - et al.
Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinomaThree meta-analyses of updated individual data
Lancet
(2000) - et al.
Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers
Radiother Oncol
(2000) - et al.
Accelerated chemoradiation to 70.6 Gy is more effective than accelerated radiation to 77.6 Gy alone—Two year results of a German multicenter randomized trial
Int J Radiat Oncol Biol Phys
(2000) - et al.
Neck dissection following radiochemotherapy of advanced head and neck cancer—For selected cases only?
Radiother Oncol
(2003) - et al.
Oxygenation of head and neck cancerChanges during radiotherapy and impact on treatment outcome
Radiother Oncol
(1999) - et al.
Squamous cell carcinoma of the head and neck treated with radiation therapyThe role of neck dissection for clinically positive neck nodes
Int J Radiat Oncol Biol Phys
(1986) - et al.
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neckReport on Intergroup Study 0034
Int J Radiat Oncol Biol Phys
(1992) - et al.
Chemo-radiotherapy as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgeryResults of EORTC phase III trial 22931
Int J Radiat Oncol Biol Phys
(2001) - et al.
Comparison of two methods of preventing central nervous system leukemia
Blood
(1973)
Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer
Int J Radiat Oncol Biol Phys
Neck dissection after twice-a-day radiotherapyMorbidity and recurrence rates
Head Neck
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancerPhase III randomized Intergroup study 0099
J Clin Oncol
Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neckA prospective randomized trial
J Clin Oncol
Stage III and IV cancers of the oropharynxResults of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy
Bull Cancer
Cited by (203)
Does Bulky Adenopathy in Human Papilloma Virus-Positive Oropharyngeal Squamous Cell Carcinoma Require a Planned Post-Treatment Neck Dissection for Occult Residual Disease?
2023, Journal of Oral and Maxillofacial SurgeryExternal validation of nodal failure prediction models including radiomics in head and neck cancer
2021, Oral OncologyCitation Excerpt :Not all clinical or radiographic persisting nodes will contain viable tumour cells and responding nodes still could recur during follow-up [1–4]. Therefore, decisions for salvage treatment based on physical examination or radiographic response on imaging could lead to over- or under-treatment [3–7]. In current practice, nodal response after radiotherapy is commonly based on neck ultrasound with or without fine needle aspiration (FNA), computed tomography (CT), positron emission tomography (PET) or magnetic resonance imaging (MRI).
Pre-treatment radiomic features predict individual lymph node failure for head and neck cancer patients
2020, Radiotherapy and OncologyCost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer
2017, European Journal of Cancer